STAT2d
A scrap of data on Amgen’s obesity drug candidate wipes out $12 billion in market value
On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value.
FierceBiotech1d
Hidden data on obesity prospect wipe $12B off Amgen market cap
The tab contains data on bone density changes in patients who received Amgen’s obesity prospect MariTide in a phase 1 ...
Wolfe Research starts Amgen at Peer Perform given approaching patent cliffs
Wolfe Research analyst Alexandria Hammond initiated coverage of Amgen (AMGN) with a Peer Perform rating. With the antibody backbone, the firm ...
Amgen rebounds after denying bone safety concerns linked to obesity drug
Amgen (NASDAQ:AMGN) shares spiked in the premarket on Wednesday after the company ruled out concerns over loss of bone ...
What’s Happening With Amgen Stock?
As an aside, in the tech space, see What’s Happening With Snap Stock? Although the recent Amgen update didn’t bode well with ...
STAT6h
AbbVie’s stumble, Amgen’s tumble and more election fallout
On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...